v3.26.3
Subsidiaries (Tables)
12 Months Ended
Jun. 30, 2026
Statements [Line Items]  
Summary of Subsidiaries
The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 1:
 
          Equity holding  
Name of entity    Country of incorporation    June 30, 2026
%
     June 30, 2025
%
 
Immutep US., Inc
   United States      100.00        100.00  
Prima BioMed Middle East FZ LLC
   United Arab Emirates      100.00        100.00  
Immutep GmbH
   Germany      100.00        100.00  
Immutep Australia Pty Ltd
   Australia      100.00        100.00  
Immutep IP Pty Ltd
   Australia      100.00        100.00  
Immutep S.A.S.
   France      100.00        100.00